Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI Worldwide, MilanCPhI Worldwide, Milan
Not Confirmed
Not Confirmed
08-10 October, 2024
Not Confirmed
Not Confirmed
28-30 September, 2024
Discovery on TargetDiscovery on Target
Not Confirmed
Not Confirmed
30 September-03 October, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI Worldwide, MilanCPhI Worldwide, Milan
Industry Trade Show
Not Confirmed
08-10 October, 2024
Industry Trade Show
Not Confirmed
28-30 September, 2024
Discovery on TargetDiscovery on Target
Industry Trade Show
Not Confirmed
30 September-03 October, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/ice-is-pioneering-sustainability-innovation-in-bile-acid-research-for-neurodegenerative-diseases
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/2024-us-elections-harris-trump-differ-on-abortion-rights-aca-public-health-spends-agree-on-need-to-cut-drug-prices
28 Jul 2022
// BUSINESSWIRE
14 Feb 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/oakrum-pharma-and-ani-pharmaceuticals-announce-the-launch-of-betaine-anhydrous-powder-the-first-generic-version-of-cystadane-betaine-anhydrous-for-oral-solution--powder-including-180-days-of-exclusivity-301481968.html
14 Jun 2021
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/aucta-pharma-and-oakrum-pharma-announce-launch-of-generic-version-of-jadenur-sprinkle-deferasirox-granules-301310888.html
22 Mar 2021
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/oakrum-pharma-and-aucta-pharma-announce-us-fda-approval-of-generic-version-of-jadenu-sprinkle-deferasirox-granules-301252585.html
15 Apr 2020
// GLOBENEWSWIRE
http://www.globenewswire.com/news-release/2020/04/15/2016587/0/en/Oakrum-Pharma-Announces-the-Launch-of-Toxo-Total-Care-Patient-Services-Program-to-Support-Pyrimethamine-25mg-Tablets.html
12 Mar 2020
// PTCOMMUNITY
https://www.ptcommunity.com/wire/oakrum-pharma-announces-launch-pyrimethamine-25mg-tablets-united-states
Details:
Through the acquisition, Eton gains access to an abbreviated new drug application for Nitisinone Capsules via Oakrum. Nitisinone is FDA approved or the treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.
Lead Product(s): Nitisinone
Therapeutic Area: Genetic Disease Brand Name: Nitisinone-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Eton Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 04, 2023
Lead Product(s) : Nitisinone
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Eton Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone
Details : Through the acquisition, Eton gains access to an abbreviated new drug application for Nitisinone Capsules via Oakrum. Nitisinone is FDA approved or the treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine ...
Brand Name : Nitisinone-Generic
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 04, 2023
Details:
JADENU (deferasirox) tablets for oral use and JADENU® Sprinkle (deferasirox) granules are indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Lead Product(s): Deferasirox
Therapeutic Area: Hematology Brand Name: Jadenu
Study Phase: ApprovedProduct Type: Small molecule
Recipient: Aucta Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2021
Lead Product(s) : Deferasirox
Therapeutic Area : Hematology
Highest Development Status : Approved
Recipient : Aucta Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Oakrum Pharma and Aucta Pharma Announce U.S. FDA Approval of Generic Version of JADENU® Sprinkle ...
Details : JADENU (deferasirox) tablets for oral use and JADENU® Sprinkle (deferasirox) granules are indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Brand Name : Jadenu
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 22, 2021
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?